ESTABLISHING A GLOBAL AND DIVERSIFIED BIOPHARMACEUTICAL COMPANY

Strategic Rationale

▪ The companies share a patient-focused mission to develop therapies that address high, unmet medical needs
▪ Advances the development of VTS-270 for the treatment of Niemann-Pick Type C1 (NPC1), currently in fully enrolled, global pivotal registration program
▪ Enhances capabilities, resources and expertise to accelerate development and successfully commercialize VTS-270
▪ Contributes to Sucampo’s goal of building an increasingly diversified, global biopharmaceutical company

Financial Highlights

▪ Sucampo acquired privately-held Vtesse for a total upfront consideration of $200 million
▪ Acquisition to be financed through the issuance of $30 million of Sucampo common shares and $170 million in cash on hand
▪ Contingent earn-out payments consist of mid-single digit to double-digit royalties on global net sales of the product at increasing net sales levels
▪ No external financing required
▪ Accretive to Sucampo earnings beginning in 2019

INCREASED FOCUS ON RARE DISEASES WITH HIGH UNMET NEED

About VTS-270

▪ Well-characterized mixture of 2-hydroxypropyl-β-cyclodextrin (HPβCD) with a specific compositional fingerprint that distinguishes it from other HPβCD mixtures
▪ Mechanism and intrathecal route of administration directly address the devastating and most commonly fatal neurological disease manifestations
▪ Pivotal Phase 2b/3 fully-enrolled multi-national study
▪ Compelling Phase 2 and pre-clinical data with clinically significant benefit as measured by disease-specific outcomes
▪ US FDA and EMA Orphan designation
▪ US FDA Breakthrough Therapy designation
▪ UK Medicines and Healthcare Products Regulatory Agency (MHRA) Promising Innovative Medicine (“PIM”) designation
▪ US FDA Rare Pediatric Disease designation

About Niemann-Pick Disease Type C1 (NPC1)

▪ Ultra-rare, progressive and fatal disease caused by defects in lipid transformation within the cell
▪ Onset from infancy into adulthood
▪ Neurological onset most common outside infantile ages
▪ Progressive and irreversible neurological manifestations
▪ Estimated 2,000-3,000 cases globally
▪ Under- and mis-diagnosed
▪ NPC results in early death in the vast majority of cases
▪ Currently no approved treatments for the disease in the U.S.

CLINICAL FOCUS

<table>
<thead>
<tr>
<th>LEAD COMPOUNDS</th>
<th>STAGE OF CLINICAL DEVELOPMENT COMPLETED</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PRE-CLINICAL</td>
</tr>
<tr>
<td>Lubiprostone - Pediatric Functional Constipation (6 years – 17 years)</td>
<td></td>
</tr>
<tr>
<td>Lubiprostone - Alternate Formulation</td>
<td></td>
</tr>
<tr>
<td>Lubiprostone - Pediatric Functional Constipation (6 months – 6 years)</td>
<td></td>
</tr>
<tr>
<td>CPP-1X/sulindac Combination Product</td>
<td></td>
</tr>
<tr>
<td>VTS-270</td>
<td></td>
</tr>
</tbody>
</table>

About Sucampo

▪ Global biopharmaceutical company that is built on the ongoing pursuit of scientific innovation and an unwavering passion for improving the lives of patients
▪ Market Products: AMITIZA and RESCULA
▪ Ticker: SCMP (NASDAQ)
▪ Market Cap*: $477 million
▪ 2016 Revenues: $230 million
▪ YearFounded: 1996
▪ Employees: 139
▪ Headquarters: Rockville, MD

About Vtesse

▪ Privately-held company focused on developing drugs for patients suffering from devastating diseases
▪ YearFounded: 2015
▪ Employees: 10
▪ Headquarters: Gaithersburg, MD

*Bloomberg market data, as of March 31, 2017